Skip to main content
logo
Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.04
+0.09 (0.43%)
At close: Mar 6, 2026, 4:00 PM EST
21.05
+0.01 (0.05%)
After-hours: Mar 6, 2026, 7:51 PM EST

Immunome Revenue

In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.

Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
342.94
Revenue / Employee
$39,215
Employees
177
Market Cap
2.38B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20256.94M-2.10M-23.23%
Dec 31, 20249.04M-4.98M-35.50%
Dec 31, 202314.02M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Apellis Pharmaceuticals1.00B
Telix Pharmaceuticals803.79M
Travere Therapeutics490.73M
Zai Lab460.16M
Adaptive Biotechnologies276.98M
Day One Biopharmaceuticals158.18M
Tango Therapeutics62.38M
Ocular Therapeutix51.95M
Revenue Rankings

IMNM News

More News